The deal with Takeda provides excellent validation for Crescendo Biologics’ exciting Humabody® platform, which has the potential of creating a range of very small, heavy-chain only therapeutic antibodies with improved properties vs. ‘standard’ humanised antibodies. We believe that 22.7%-owned Crescendo represents one of the highest-potential companies in Imperial Innovations’ portfolio. We re-iterate our Buy recommendation.
